The Added Value of Liquid Antipsychotics: The Case of Quetiapine

Author(s): Georgios Papazisis*, Spyridon Siafis.

Journal Name: Current Clinical Pharmacology

Volume 14 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Antipsychotic drugs are the cornerstone of schizophrenia treatment and are also indicated for other psychotic and mood disorders. Different antipsychotic drugs and their formulations are available, though liquid forms have been overlooked.

Methods: Herein the added value of liquid antipsychotics is reviewed, with a focus on the recently introduced liquid quetiapine, a frequently used antipsychotic.

Results: Liquid antipsychotics are easily administrated via the preferable oral route, while compliance under supervised administration is transparent. Liquid forms could be preferred in patients with swallowing difficulties, which are common in elderly patients and often concealed. In this population, the availability of liquid antipsychotics could prevent errors in medication administration, which could possibly render caregivers labile to any harm caused to the patient. Aspiration, however, remains a risk with liquid formulations. Common errors in medication administration are the omission of treatment and alteration of solid oral formulations. Regarding quetiapine, omission of treatment could be associated with non-adherence as well as discontinuation symptoms, while alteration of extended release formulation could alter its pharmacokinetics. Mildly agitated and cooperative patients are another target population of liquid antipsychotics, which can induce fast sedation avoiding involuntary intramuscular injections. The combination of sedative properties and low incidence of extrapyramidal symptoms makes liquid quetiapine a valuable option for these patients, yet the current evidence is limited.

Conclusion: The liquid form of quetiapine can facilitate pharmacotherapy of schizophrenia and can be defined as value added medicine bringing key benefits not only to the patients and caregivers but also to the health care system.

Keywords: Antipsychotic, quetiapine, liquid, schizophrenia, dysphagia, agitation.

[1]
Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015; 114(1): 169-79.
[http://dx.doi.org/10.1093/bmb/ldv017] [PMID: 25957394]
[2]
Weiden PJ. Switching in the era of atypical antipsychotics. An updated review. Postgrad Med 2006; (Spec No): 27-44.
[PMID: 17128659]
[3]
Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014; 5: 43-62.
[http://dx.doi.org/10.2147/PROM.S42735] [PMID: 25061342]
[4]
Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 996-1008.
[http://dx.doi.org/10.1016/j.pnpbp.2006.03.031] [PMID: 16678954]
[5]
Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011; 14(2): 269-84.
[http://dx.doi.org/10.1017/S1461145710001380] [PMID: 21208500]
[6]
NHS. Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults Oct 2016.
[7]
Mutsatsa S, Bressington D. Oral liquid antipsychotic formula-tion in the treatment of psychosis. Br J Mental Health Nurs 2013; 2(3): 126-7.
[http://dx.doi.org/10.12968/bjmh.2013.2.3.126]
[8]
Value Added Medicines. Time to Adjust the HTA Decision Frameworks 2017.
[9]
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 2008; 33(10): 2303-12.
[http://dx.doi.org/10.1038/sj.npp.1301646] [PMID: 18059438]
[10]
straZenecaUK. Seroquel 25 mg film-coated tablets-Summary of Product Characteristics (SPC) - (eMC) 2016 [Available from: https://www.medicines.org.uk/emc/product/5495/smpc
[11]
AstraZenecaUK. Seroquel XL 50 mg prolonged-release tab-lets- Summary of Product Characteristics (SPC) - (eMC) 2016 [Available from: https://www.medicines.org.uk/emc/product/6363/smpc
[12]
FDA. SEROQUEL (quetiapine fumarate): Highlights of pre-scribing information. 2013 [Available from: https://www.accessdata. fda.gov/drugsatfda_docs/label/2013/020639s061lbl.pdf
[13]
Werner FM, Coveñas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf 2014; 13(8): 1031-42.
[http://dx.doi.org/10.1517/14740338.2014.935761] [PMID: 24975932]
[14]
Carney AC. Efficacy of quetiapine off-label uses: data synthesis. J Psychosoc Nurs Ment Health Serv 2013; 51(8): 11-8.
[http://dx.doi.org/10.3928/02793695-20130709-01] [PMID: 23848159]
[15]
RosemontPharmaceuticals. Quetiapine Rosemont 20mg/ml Oral Suspension-Summary of Product Characteristics (SPC) - (eMC) 2017 [Available from: https://www.medicines.org.uk/emc/product/2516/smpc
[17]
Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm 2012; 430(1-2): 197-206.
[http://dx.doi.org/10.1016/j.ijpharm.2012.04.022] [PMID: 22525080]
[18]
Marquis J, Schneider MP, Payot V, et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm 2013; 35(6): 1130-6.
[http://dx.doi.org/10.1007/s11096-013-9836-2] [PMID: 23963541]
[19]
Llorca PM. Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Ther Deliv 2011; 2(5): 611-22.
[http://dx.doi.org/10.4155/tde.11.32] [PMID: 22833978]
[20]
Strachan I, Greener M. Medication-related swallowing diffi-culties may be more common than we realise. Pharm Pract (Granada) 2005; 15(10): 411-4.
[21]
Kulkarni DP, Kamath VD, Stewart JT. Swallowing Disorders in Schizophrenia. Dysphagia 2017; 32(4): 467-71.
[http://dx.doi.org/10.1007/s00455-017-9802-6] [PMID: 28447217]
[22]
Miarons Font M, Rofes Salsench L. Antipsychotic medication and oropharyngeal dysphagia: systematic review. Eur J Gastroenterol Hepatol 2017; 29(12): 1332-9.
[http://dx.doi.org/10.1097/MEG.0000000000000983] [PMID: 29023321]
[23]
Stone M. Prescribing in patients with dysphagia. Nurse Pre-scribing 2014; 12(10): 504-7.
[http://dx.doi.org/10.12968/npre.2014.12.10.504]
[24]
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-62.
[http://dx.doi.org/10.1016/S0140-6736(13)60733-3] [PMID: 23810019]
[25]
Serrano Santos JM, Poland F, Wright D, Longmore T. Medicines administration for residents with dysphagia in care homes: A small scale observational study to improve practice. Int J Pharm 2016; 512(2): 416-21.
[http://dx.doi.org/10.1016/j.ijpharm.2016.02.036] [PMID: 26906457]
[26]
Chiappini S, Schifano F. Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions’ Database. J Clin Psychopharmacol 2018; 38(1): 72-9.
[PMID: 29210868]
[27]
Haw C, Stubbs J. Administration of medicines in food and drink: a study of older inpatients with severe mental illness. Int Psychogeriatr 2010; 22(3): 409-16.
[http://dx.doi.org/10.1017/S1041610209991669] [PMID: 20078907]
[28]
Logrippo S, Ricci G, Sestili M, et al. Oral drug therapy in elderly with dysphagia: between a rock and a hard place! Clin Interv Aging 2017; 12: 241-51.
[http://dx.doi.org/10.2147/CIA.S121905] [PMID: 28203065]
[29]
Thong MY, Manrique YJ, Steadman KJ. Drug loss while crushing tablets: Comparison of 24 tablet crushing devices. PLoS One 2018; 13(3)e0193683
[http://dx.doi.org/10.1371/journal.pone.0193683] [PMID: 29494695]
[30]
Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008; 52(5): 541-7.
[http://dx.doi.org/10.1016/j.annemergmed.2008.03.016] [PMID: 18433934]
[31]
Salmon D, Pont E, Chevallard H, et al. Pharmaceutical and safety considerations of tablet crushing in patients undergoing enteral intubation. Int J Pharm 2013; 443(1-2): 146-53.
[http://dx.doi.org/10.1016/j.ijpharm.2012.12.038] [PMID: 23299084]
[32]
Fodil M, Nghiem D, Colas M, et al. Assessment of Clinical Practices for Crushing Medication in Geriatric Units. J Nutr Health Aging 2017; 21(8): 904-8.
[http://dx.doi.org/10.1007/s12603-017-0886-3] [PMID: 28972243]
[33]
Kelly J, Wright D, Wood J. Medicine administration errors in patients with dysphagia in secondary care: a multi-centre observational study. J Adv Nurs 2011; 67(12): 2615-27.
[http://dx.doi.org/10.1111/j.1365-2648.2011.05700.x] [PMID: 21615463]
[34]
Liu F, Ghaffur A, Bains J, Hamdy S. Acceptability of oral solid medicines in older adults with and without dysphagia: A nested pilot validation questionnaire based observational study. Int J Pharm 2016; 512(2): 374-81.
[http://dx.doi.org/10.1016/j.ijpharm.2016.03.007] [PMID: 26970368]
[35]
Carnaby-Mann G, Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 2005; 131(11): 970-5.
[http://dx.doi.org/10.1001/archotol.131.11.970] [PMID: 16301368]
[36]
Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs 2014; 74(16): 1871-89.
[http://dx.doi.org/10.1007/s40265-014-0297-2] [PMID: 25274536]
[37]
Dundar Y, Greenhalgh J, Richardson M, Dwan K. Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. Hum Psychopharmacol 2016; 31(4): 268-85.
[http://dx.doi.org/10.1002/hup.2535] [PMID: 27151529]
[38]
Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: Expert consensus. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2016; 17(2): 86- 128.
[39]
Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy 2016; 5(1)1264717
[http://dx.doi.org/10.1080/20016689.2017.1264717] [PMID: 28265347]
[40]
Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature 2012; 492(7428): 215-20.
[http://dx.doi.org/10.1038/nature11691] [PMID: 23235874]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2019
Page: [101 - 107]
Pages: 7
DOI: 10.2174/1574884713666181102145236

Article Metrics

PDF: 37
HTML: 4